---
document_datetime: 2025-11-23 08:45:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-mylan-pharma.html
document_name: pregabalin-mylan-pharma.html
version: success
processing_time: 0.1099639
conversion_datetime: 2025-12-27 23:07:12.939845
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pregabalin Mylan Pharma

[RSS](/en/individual-human-medicine.xml/66844)

##### Withdrawn

This medicine's authorisation has been withdrawn

pregabalin

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pregabalin Mylan Pharma](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 3 November 2021 the European Commission withdrew the marketing authorisation for Pregabalin Mylan Pharma (pregabalin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Mylan S.A.S, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Pregabalin Mylan Pharma was granted marketing authorisation in the EU on 25 June 2015 for the treatment of neuropathic pain, epilepsy and generalised anxiety disorder (GAD). The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2019.

Pregabalin Mylan Pharma is a generic medicine of Lyrica. There are other generic medicinal products of Lyrica authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Pregabalin Mylan Pharma is updated to indicate that the marketing authorisation is no longer valid.

Pregabalin Mylan Pharma : EPAR - Summary for the public

English (EN) (706.42 KB - PDF)

**First published:** 31/07/2015

**Last updated:** 26/04/2022

[View](/en/documents/overview/pregabalin-mylan-pharma-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-149)

български (BG) (777.09 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/bg/documents/overview/pregabalin-mylan-pharma-epar-summary-public_bg.pdf)

español (ES) (682.37 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/es/documents/overview/pregabalin-mylan-pharma-epar-summary-public_es.pdf)

čeština (CS) (759.08 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/cs/documents/overview/pregabalin-mylan-pharma-epar-summary-public_cs.pdf)

dansk (DA) (680.4 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/da/documents/overview/pregabalin-mylan-pharma-epar-summary-public_da.pdf)

Deutsch (DE) (684.58 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/de/documents/overview/pregabalin-mylan-pharma-epar-summary-public_de.pdf)

eesti keel (ET) (679.79 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/et/documents/overview/pregabalin-mylan-pharma-epar-summary-public_et.pdf)

ελληνικά (EL) (782.13 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/el/documents/overview/pregabalin-mylan-pharma-epar-summary-public_el.pdf)

français (FR) (683.01 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/fr/documents/overview/pregabalin-mylan-pharma-epar-summary-public_fr.pdf)

hrvatski (HR) (703.49 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/hr/documents/overview/pregabalin-mylan-pharma-epar-summary-public_hr.pdf)

italiano (IT) (680.99 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/it/documents/overview/pregabalin-mylan-pharma-epar-summary-public_it.pdf)

latviešu valoda (LV) (757.18 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/lv/documents/overview/pregabalin-mylan-pharma-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (708.21 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/lt/documents/overview/pregabalin-mylan-pharma-epar-summary-public_lt.pdf)

magyar (HU) (751.62 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/hu/documents/overview/pregabalin-mylan-pharma-epar-summary-public_hu.pdf)

Malti (MT) (990.97 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/mt/documents/overview/pregabalin-mylan-pharma-epar-summary-public_mt.pdf)

Nederlands (NL) (681.89 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/nl/documents/overview/pregabalin-mylan-pharma-epar-summary-public_nl.pdf)

polski (PL) (757.19 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/pl/documents/overview/pregabalin-mylan-pharma-epar-summary-public_pl.pdf)

português (PT) (682.22 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/pt/documents/overview/pregabalin-mylan-pharma-epar-summary-public_pt.pdf)

română (RO) (707.14 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/ro/documents/overview/pregabalin-mylan-pharma-epar-summary-public_ro.pdf)

slovenčina (SK) (758.03 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/sk/documents/overview/pregabalin-mylan-pharma-epar-summary-public_sk.pdf)

slovenščina (SL) (750.17 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/sl/documents/overview/pregabalin-mylan-pharma-epar-summary-public_sl.pdf)

Suomi (FI) (680.73 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/fi/documents/overview/pregabalin-mylan-pharma-epar-summary-public_fi.pdf)

svenska (SV) (680.69 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/sv/documents/overview/pregabalin-mylan-pharma-epar-summary-public_sv.pdf)

Pregabalin Mylan Pharma : EPAR - Risk-management-plan summary

English (EN) (650.44 KB - PDF)

**First published:** 31/07/2015

**Last updated:** 26/04/2022

[View](/en/documents/rmp-summary/pregabalin-mylan-pharma-epar-risk-management-plan-summary_en.pdf)

## Product information

Pregabalin Mylan Pharma : EPAR - Product Information

English (EN) (1.11 MB - PDF)

**First published:** 31/07/2015

**Last updated:** 26/04/2022

[View](/en/documents/product-information/pregabalin-mylan-pharma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-62)

български (BG) (2.89 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/bg/documents/product-information/pregabalin-mylan-pharma-epar-product-information_bg.pdf)

español (ES) (1.06 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/es/documents/product-information/pregabalin-mylan-pharma-epar-product-information_es.pdf)

čeština (CS) (2.25 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/cs/documents/product-information/pregabalin-mylan-pharma-epar-product-information_cs.pdf)

dansk (DA) (1.02 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/da/documents/product-information/pregabalin-mylan-pharma-epar-product-information_da.pdf)

Deutsch (DE) (1.12 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/de/documents/product-information/pregabalin-mylan-pharma-epar-product-information_de.pdf)

eesti keel (ET) (1.02 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/et/documents/product-information/pregabalin-mylan-pharma-epar-product-information_et.pdf)

ελληνικά (EL) (3.04 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/el/documents/product-information/pregabalin-mylan-pharma-epar-product-information_el.pdf)

français (FR) (1.06 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/fr/documents/product-information/pregabalin-mylan-pharma-epar-product-information_fr.pdf)

hrvatski (HR) (1.1 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/hr/documents/product-information/pregabalin-mylan-pharma-epar-product-information_hr.pdf)

íslenska (IS) (1.04 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/is/documents/product-information/pregabalin-mylan-pharma-epar-product-information_is.pdf)

italiano (IT) (1.07 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/it/documents/product-information/pregabalin-mylan-pharma-epar-product-information_it.pdf)

latviešu valoda (LV) (2.29 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/lv/documents/product-information/pregabalin-mylan-pharma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.13 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/lt/documents/product-information/pregabalin-mylan-pharma-epar-product-information_lt.pdf)

magyar (HU) (2.2 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/hu/documents/product-information/pregabalin-mylan-pharma-epar-product-information_hu.pdf)

Malti (MT) (2.3 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/mt/documents/product-information/pregabalin-mylan-pharma-epar-product-information_mt.pdf)

Nederlands (NL) (1.09 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/nl/documents/product-information/pregabalin-mylan-pharma-epar-product-information_nl.pdf)

norsk (NO) (1.03 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/no/documents/product-information/pregabalin-mylan-pharma-epar-product-information_no.pdf)

polski (PL) (2.37 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/pl/documents/product-information/pregabalin-mylan-pharma-epar-product-information_pl.pdf)

português (PT) (1.13 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/pt/documents/product-information/pregabalin-mylan-pharma-epar-product-information_pt.pdf)

română (RO) (1.16 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/ro/documents/product-information/pregabalin-mylan-pharma-epar-product-information_ro.pdf)

slovenčina (SK) (2.17 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/sk/documents/product-information/pregabalin-mylan-pharma-epar-product-information_sk.pdf)

slovenščina (SL) (2.17 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/sl/documents/product-information/pregabalin-mylan-pharma-epar-product-information_sl.pdf)

Suomi (FI) (1.05 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/fi/documents/product-information/pregabalin-mylan-pharma-epar-product-information_fi.pdf)

svenska (SV) (1.05 MB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/sv/documents/product-information/pregabalin-mylan-pharma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/2006 14/01/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pregabalin Mylan Pharma : EPAR - All Authorised presentations

English (EN) (629.49 KB - PDF)

**First published:** 31/07/2015

**Last updated:** 26/04/2022

[View](/en/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-794)

български (BG) (794.06 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/bg/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_bg.pdf)

español (ES) (633.98 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/es/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (710.54 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/cs/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (632.7 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/da/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (633.33 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/de/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (635.71 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/et/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (733.45 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/el/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_el.pdf)

français (FR) (638.81 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/fr/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (663.87 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/hr/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (628.15 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/is/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (631.47 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/it/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (710.56 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/lv/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (674.65 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/lt/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (695.47 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/hu/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (718.63 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/mt/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (631.35 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/nl/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (630.24 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/no/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_no.pdf)

polski (PL) (683.04 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/pl/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_pl.pdf)

português (PT) (643.45 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/pt/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_pt.pdf)

română (RO) (648.99 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/ro/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (690.69 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/sk/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (717.93 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/sl/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (632.1 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/fi/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (633.74 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

26/04/2022

[View](/sv/documents/all-authorised-presentations/pregabalin-mylan-pharma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pregabalin Mylan Pharma Active substance pregabalin International non-proprietary name (INN) or common name pregabalin Therapeutic area (MeSH)

- Anxiety Disorders
- Neuralgia
- Epilepsy

Anatomical therapeutic chemical (ATC) code N03AX16

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

**Epilepsy**

Pregabalin Mylan Pharma is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

**Generalised Anxiety Disorder**

Pregabalin Mylan Pharma is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

## Authorisation details

EMA product number EMEA/H/C/003962

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan S.A.S.

117 Allee des Parcs

Opinion adopted 23/04/2015 Marketing authorisation issued 25/06/2015 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pregabalin Mylan Pharma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (776.51 KB - PDF)

**First published:** 19/02/2016

**Last updated:** 26/04/2022

[View](/en/documents/procedural-steps-after/pregabalin-mylan-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pregabalin Mylan Pharma : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/90102/2015

English (EN) (1.3 MB - PDF)

**First published:** 31/07/2015

**Last updated:** 26/04/2022

[View](/en/documents/assessment-report/pregabalin-mylan-pharma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pregabalin Mylan Pharma

Adopted

Reference Number: EMA/CHMP/236014/2015

English (EN) (661.89 KB - PDF)

**First published:** 24/04/2015

**Last updated:** 26/04/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-mylan-pharma_en.pdf)

#### News on Pregabalin Mylan Pharma

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-april-2015) 24/04/2015

**This page was last updated on** 26/04/2022

## Share this page

[Back to top](#main-content)